Aug 11, 2021 8:21am EDT FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Jul 29, 2021 4:01pm EDT Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jul 27, 2021 8:00am EDT Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Jul 22, 2021 4:08pm EDT Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
Jul 20, 2021 7:00am EDT Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
May 03, 2021 4:32pm EDT Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 03, 2021 7:00am EDT Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
Apr 29, 2021 7:00am EDT Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's Largest A.I. Platform for Oncology-Focused Drug Development & Rescue
Apr 26, 2021 4:30pm EDT Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET
Apr 26, 2021 7:45am EDT Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
